Status:
COMPLETED
Evaluating the Dose Timing (Morning vs Evening) of Endocrine Therapy and Its Effects on Tolerability and Compliance
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Endocrine therapy is an established treatment for hormone receptor-positive breast cancer, but can cause significant side effects with deterioration in quality of life. The side effects of all forms o...
Detailed Description
Endocrine therapy is an established treatment for hormone receptor-positive breast cancer, but can cause significant side effects with deterioration in quality of life. The side effects of all forms o...
Eligibility Criteria
Inclusion
- Patients with an early stage or locally advanced hormonal receptor positive breast cancer
- Plan to receive endocrine therapy
- 18 years of age or older
- Able to provide oral consent
- Willing and able to complete questionnaires as per study protocol
Exclusion
- Metastatic cancer
- Previous endocrine therapy for breast cancer
- Plan to receive adjuvant abemaciclib
Key Trial Info
Start Date :
June 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 29 2023
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT04864405
Start Date
June 30 2021
End Date
July 29 2023
Last Update
January 8 2026
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
2
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada, P7B 6V4